Ziftomenib, a potent menin-KMT2A inhibitor, induces leukemia regression and reduces tumor burden in models of KMT2A-rearranged leukemia, with strong gene downregulation.
- 6 cites
Moving in Blood.
Rebuilt
Ziftomenib, a potent menin-KMT2A inhibitor, induces leukemia regression and reduces tumor burden in models of KMT2A-rearranged leukemia, with strong gene downregulation.
Newest first · last 60 days
OCRL deficiency in Lowe syndrome causes mitochondrial dysfunction, impaired cilia-related Sonic Hedgehog signaling, and disrupted neuronal differentiation across multiple models.
Aminopeptidase N serves as a receptor for hedgehog merbecoviruses, with species-specific binding revealed by cryo-EM analysis.
Cilia beating of ependymal cells maintains adult neural stem cell quiescence through PKD1/2-TRPM3-mediated mechanical forces, with brief inhibition activating stem cells in vivo.
A novel CDC45 variant and a recurrent East Asian variant were identified in a Chinese MGORS7 patient, expanding the mutational spectrum of the disorder.
Bi-allelic loss-of-function variants in CDK20 cause a severe ciliopathy with midline brain and facial anomalies in seven individuals from five families.
Functional validation confirms the PKD1 c.7489 + 5G>A variant causes pathogenic exon skipping in an ADPKD family, enabling successful prevention of disease transmission.
Ziftomenib, a potent menin-KMT2A inhibitor, induces leukemia regression and reduces tumor burden in models of KMT2A-rearranged leukemia, with strong gene downregulation.
Journals this month
Moving areas, week to 3 Oct 2026